Chemotherapy News and Research

Latest Chemotherapy News and Research

Cetuximab fails in second-line combination for recurrent NSCLC

Results from a phase III trial indicate that cetuximab should not be given alongside chemotherapy in patients with recurrent non-small-cell lung cancer after platinum-based therapy.

13 Dec 2013

Deep genome sequencing used to predict clinical outcomes in patients with breast cancer tumors

New research from University Hospitals (UH) Case Medical Center Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University examined how changes in the genetic composition of breast cancer tumors after brief exposure to either biologic therapy or chemotherapy can predict future clinical outcomes in patients.

13 Dec 2013

ESMO’s position paper highlights role of oncologists toward quality cancer care

Medical oncologists have a vital role to play in cancer care, particularly as treatments become ever more complex, a new position statement from the European Society for Medical Oncology says.

13 Dec 2013

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

VG Life Sciences, a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.

13 Dec 2013

AVEO announces data from planned interim analysis of Phase 2 BATON study in CRC patients

AVEO Oncology today announced that data from a planned interim analysis of the Phase 2 BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.

13 Dec 2013

Genomic tests help in selecting the most effective therapy for breast cancer

Genomic tests that determine the molecular subtype of a woman's breast cancer provide a more precise prognosis and valuable guidance about the best treatment, according to new research led by Massimo Cristofanilli, M.D, Director of the Jefferson Breast Care Center at the Kimmel Cancer Center (KCC) and Thomas Jefferson University and Hospitals.

13 Dec 2013

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

13 Dec 2013

Novel ISM strategy enables selection of potentially effective cancer therapies for patients

A new individualized systems medicine strategy, developed at the Institute for Molecular Medicine Finland FIMM and the Helsinki University Central Hospital, enables a selection of potentially effective cancer therapies for individual patients. The promising results achieved by applying this strategy to chemoresistant adult acute myeloid leukemia patients have been recently published in the Cancer Discovery journal.

13 Dec 2013

Breast cancer survivors taking AIs may experience reduction in joint pain on exercising

Breast cancer survivors taking aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane experienced a reduction in joint pain if they exercised while on treatment, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

13 Dec 2013

Over-use of staging procedures more prevalent in younger, early-stage breast cancer patients

More than one third of younger, early stage breast cancer patients undergo unnecessary imaging procedures - including position emission tomography (PET), computed tomography (CT), nuclear medicine bone scans (NMBS) and tumor markers (TM) -- at the time of staging and diagnosis, according to research from The University of Texas MD Anderson Cancer Center.

13 Dec 2013

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

Researchers at the Roswell Park Cancer Institute Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers.

13 Dec 2013

New treatment needed for women with HER2- and hormone receptor-positive breast cancer with PIK3CA mutation

Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

12 Dec 2013

Results from NeoALTTO trial to be presented at 2013 San Antonio Breast Cancer Symposium

Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

12 Dec 2013

Senhwa Biosciences raises additional $17 million USD in Series B financing

Senhwa Biosciences, Inc. has raised an additional $17 million USD in a Series B financing to drive its anticancer agents through critical clinical trials, the company announced today.

12 Dec 2013

Combination therapy safe and active in follicular lymphoma

One drug attacks tumor cells directly, the other treats the immune system by taking the brakes off T cell response.

12 Dec 2013

New reports demonstrate the effectiveness of modified T cells in treating blood-borne cancers

At the 2013 American Society of Hematology meeting in Dec. 2013, James Kochenderfer, M.D., investigator in the Experimental Transplantation and Immunology Branch, NCI, presented findings from two clinical trials evaluating the use of genetically modified immune system T cells as cancer therapy.

12 Dec 2013

Study: Taxol and Herceptin highly effective for lower-risk breast cancer patients

A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.

12 Dec 2013

Early docetaxel drug with ADT increases survival of men with metastatic prostate cancer

Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early results from a National Institutes of Health-supported randomized controlled clinical trial.

12 Dec 2013

Immunocellular Therapeutics reports positive results from ICT-107 Phase II study in glioblastoma patients

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial.

12 Dec 2013

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cetuximab fails in second-line combination for recurrent NSCLC

Deep genome sequencing used to predict clinical outcomes in patients with breast cancer tumors

ESMO’s position paper highlights role of oncologists toward quality cancer care

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

AVEO announces data from planned interim analysis of Phase 2 BATON study in CRC patients

Genomic tests help in selecting the most effective therapy for breast cancer

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Novel ISM strategy enables selection of potentially effective cancer therapies for patients

Breast cancer survivors taking AIs may experience reduction in joint pain on exercising

Over-use of staging procedures more prevalent in younger, early-stage breast cancer patients

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

New treatment needed for women with HER2- and hormone receptor-positive breast cancer with PIK3CA mutation

Results from NeoALTTO trial to be presented at 2013 San Antonio Breast Cancer Symposium

Senhwa Biosciences raises additional $17 million USD in Series B financing

Combination therapy safe and active in follicular lymphoma

New reports demonstrate the effectiveness of modified T cells in treating blood-borne cancers

Study: Taxol and Herceptin highly effective for lower-risk breast cancer patients

Early docetaxel drug with ADT increases survival of men with metastatic prostate cancer

Immunocellular Therapeutics reports positive results from ICT-107 Phase II study in glioblastoma patients

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in